Risks and Management of Colitis

Introduction to Colitis

Colitis refers to inflammation of the colon, which can occur in various forms including ulcerative colitis, Crohn's disease with colonic involvement, microscopic colitis, and other inflammatory conditions 1, 2

Antidiarrheal medications can mask worsening symptoms while allowing underlying inflammation to progress unchecked 3
There is a theoretical risk that high-dose antidiarrheals may predispose to toxic dilatation, especially in patients with active inflammation 4

The European Society of Gastrointestinal Endoscopy recommends first-line treatments including aminosalicylates (mesalazine 2-4g daily or balsalazide) for mild to moderate ulcerative colitis 2, 5
Topical mesalazine is recommended for distal ulcerative colitis, often in combination with oral therapy 2
Corticosteroids (prednisolone 40mg daily) are appropriate for moderate to severe ulcerative colitis or when aminosalicylates fail 2
Maintenance therapy with aminosalicylates, azathioprine, or mercaptopurine is recommended to prevent relapse in ulcerative colitis 1, 6
Treatment for Crohn's disease depends on disease location, pattern, and severity, with options including high-dose mesalazine (4g/day) for mild disease, corticosteroids for moderate to severe disease, and biologics for refractory cases 1

Patients with colitis should be regularly assessed for disease activity using clinical indices 5
Those with severe disease require hospital admission and joint management by gastroenterology and surgery 2, 6
Regular monitoring of inflammatory markers, electrolytes, and clinical symptoms is essential 6

The American Gastroenterological Association recommends starting standard-dose mesalamine (2-3 grams/day) or diazo-bonded 5-ASA as first-line therapy for mild-to-moderate ulcerative colitis, with the option to add rectal mesalamine for extensive or left-sided disease to improve remission rates 7, 8
For patients with ulcerative colitis who do not respond to standard dosing, the guideline suggests escalating to high-dose mesalamine (>3 grams/day) with rectal mesalamine, and considering corticosteroids (prednisone 40mg daily or budesonide MMX) for those refractory to optimized 5-ASA therapy 7, 8, 9
The European Crohn’s and Colitis Organisation recommends high-dose mesalazine (4 grams/day) for mild ileocolonic Crohn's disease, oral prednisolone 40mg daily for moderate-to-severe disease, and intravenous corticosteroids for severe disease, with the option to consider metronidazole 10-20mg/kg/day for colonic or treatment-resistant disease 10

When symptomatic relief is necessary, loperamide may be used at the lowest effective dose, but only after ruling out severe disease, and with close monitoring for worsening symptoms, fever, or abdominal distension, and discontinuation if symptoms worsen or fail to improve within 48 hours 8